• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部癌放疗后甲状腺功能减退:文献系统综述及提高治疗比的机会

Hypothyroidism following Radiotherapy for Head and Neck Cancer: A Systematic Review of the Literature and Opportunities to Improve the Therapeutic Ratio.

作者信息

Rooney Michael K, Andring Lauren M, Corrigan Kelsey L, Bernard Vincent, Williamson Tyler D, Fuller Clifton D, Garden Adam S, Gunn Brandon, Lee Anna, Moreno Amy C, Morrison William H, Phan Jack, Rosenthal David I, Spiotto Michael, Frank Steven J

机构信息

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Cancers (Basel). 2023 Aug 29;15(17):4321. doi: 10.3390/cancers15174321.

DOI:10.3390/cancers15174321
PMID:37686597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10486996/
Abstract

(1) Background: Radiotherapy (RT) is a central component for the treatment of many head and neck cancers. In this systematic review of the literature, we aimed to characterize and quantify the published evidence on RT-related hypothyroidism, including estimated incidence, clinical risk factors, and dosimetric parameters that may be used to guide clinical decision making. Furthermore, we aimed to identify potential areas of improvement in the prevention and clinical management of RT-induced hypothyroidism, including the role of modern advanced therapeutic techniques. (2) Methods: We conducted a systemic review of the literature in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed and Google Scholar were searched to identify original research articles describing the incidence, mechanism, dosimetry, treatment, or prevention of radiation-related hypothyroidism for adults receiving RT for the treatment of head and neck cancers. The snowball method was used to identify additional articles. For identified articles, we tabulated several datapoints, including publication date, patient sample size, estimated hypothyroidism incidence, cancer site/type, follow-up period, radiation modality and technique, use of multimodality therapy, method of thyroid function evaluation, and proposed dosimetric predictors of hypothyroidism. (3) Results: One hundred and eleven articles met inclusion criteria, reflecting a range of head and neck cancer subtypes. There was a large variation in the estimated incidence of RT-related hypothyroidism, with a median estimate of 36% (range 3% to 79%). Reported incidence increased in later publication dates, which was likely related to improved screening and longer follow up. There were a wide variety of predictive metrics used to identify patients at high risk of hypothyroidism, the most common of which were volumetric and mean dosimetrics related to the thyroid gland (Vxx%, Dmean). More recently, there has been increasing evidence to suggest that the thyroid gland volume itself and the volume of the thyroid gland spared from high-dose radiation (VSxx) may better predict thyroid function after RT. There were no identified studies investigating the role of advanced radiotherapeutic techniques such as MRI-guided RT or particle therapy to decrease RT-related hypothyroidism. Conclusions: Hypothyroidism is a common toxicity resulting from therapeutic radiation for head and neck cancer with recent estimates suggesting 40-50% of patients may experience hypothyroidism after treatment. Dosimetric predictive models are increasingly able to accurately identify patients at risk of hypothyroidism, especially those utilizing thyroid VS metrics. Further investigation regarding the potential for advanced radiotherapeutic therapies to decrease RT-induced thyroid dysfunction is needed.

摘要

(1)背景:放射治疗(RT)是许多头颈癌治疗的核心组成部分。在本系统文献综述中,我们旨在描述和量化已发表的关于放疗相关甲状腺功能减退的证据,包括估计发病率、临床风险因素以及可用于指导临床决策的剂量学参数。此外,我们旨在确定放疗诱发甲状腺功能减退的预防和临床管理方面潜在的改进领域,包括现代先进治疗技术的作用。(2)方法:我们按照系统评价和Meta分析的首选报告项目(PRISMA)指南对文献进行了系统综述。检索了PubMed和谷歌学术,以识别描述接受头颈癌放疗的成人放射性甲状腺功能减退的发病率、机制、剂量学、治疗或预防的原始研究文章。采用滚雪球法识别其他文章。对于已识别的文章,我们列出了几个数据点,包括发表日期、患者样本量、估计的甲状腺功能减退发病率、癌症部位/类型、随访期、放疗方式和技术、多模态治疗的使用、甲状腺功能评估方法以及提出的甲状腺功能减退剂量学预测指标。(3)结果:111篇文章符合纳入标准,反映了一系列头颈癌亚型。放疗相关甲状腺功能减退的估计发病率差异很大,中位估计值为36%(范围3%至79%)。报告的发病率在较晚的发表日期有所增加,这可能与筛查改善和随访时间延长有关。有多种预测指标用于识别甲状腺功能减退高危患者,其中最常见的是与甲状腺相关的容积和平均剂量学指标(Vxx%,Dmean)。最近,越来越多的证据表明,甲状腺体积本身以及未受高剂量辐射的甲状腺体积(VSxx)可能更好地预测放疗后的甲状腺功能。没有已识别的研究调查诸如MRI引导放疗或粒子治疗等先进放疗技术在降低放疗相关甲状腺功能减退方面的作用。结论:甲状腺功能减退是头颈癌治疗性放疗导致的常见毒性反应,最近的估计表明40 - 50%的患者在治疗后可能会出现甲状腺功能减退。剂量学预测模型越来越能够准确识别甲状腺功能减退高危患者,尤其是那些使用甲状腺VS指标的模型。需要进一步研究先进放疗疗法降低放疗诱发甲状腺功能障碍的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2c/10486996/8817f1807b43/cancers-15-04321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2c/10486996/0dcdbe333a9a/cancers-15-04321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2c/10486996/c93bd82a92ea/cancers-15-04321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2c/10486996/8817f1807b43/cancers-15-04321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2c/10486996/0dcdbe333a9a/cancers-15-04321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2c/10486996/c93bd82a92ea/cancers-15-04321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2c/10486996/8817f1807b43/cancers-15-04321-g003.jpg

相似文献

1
Hypothyroidism following Radiotherapy for Head and Neck Cancer: A Systematic Review of the Literature and Opportunities to Improve the Therapeutic Ratio.头颈部癌放疗后甲状腺功能减退:文献系统综述及提高治疗比的机会
Cancers (Basel). 2023 Aug 29;15(17):4321. doi: 10.3390/cancers15174321.
2
Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review.头颈部癌放疗后原发性甲状腺功能减退的剂量-体积预测因素:一项系统综述
Clin Transl Radiat Oncol. 2022 Jan 24;33:83-92. doi: 10.1016/j.ctro.2022.01.001. eCollection 2022 Mar.
3
Radiation-induced hypothyroidism after treatment of head and neck cancer.头颈部癌治疗后放射性甲状腺功能减退症
Dan Med J. 2016 Mar;63(3).
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Functional and biochemical changes in the thyroid gland following exposure to therapeutic doses of external beam radiotherapy in the head-and-neck cancer patients.头颈部癌症患者接受外照射治疗后甲状腺的功能和生化变化。
J Cancer Res Ther. 2021 Jul-Sep;17(4):1025-1030. doi: 10.4103/jcrt.JCRT_148_19.
6
Correlative study of dose to thyroid and incidence of subsequent dysfunction after head and neck radiation.头颈部放疗后甲状腺剂量与后续功能障碍发生率的相关性研究。
Head Neck. 2017 Mar;39(3):548-554. doi: 10.1002/hed.24643. Epub 2016 Dec 1.
7
The incidence of hypothyroidism after radiotherapy for head and neck cancer.头颈部癌放疗后甲状腺功能减退的发生率。
B-ENT. 2016;12(4):257-262.
8
[Secondary hypothyroidism after cervical irradiation: systematic evaluation of thyroid function in follow-up].[颈部放疗后继发性甲状腺功能减退:随访中甲状腺功能的系统评估]
Acta Med Port. 2014 Jul-Aug;27(4):467-72. Epub 2014 Aug 29.
9
Dose-volumetric parameters for predicting hypothyroidism after radiotherapy for head and neck cancer.预测头颈部癌症放疗后甲状腺功能减退的剂量-体积参数。
Jpn J Clin Oncol. 2014 Apr;44(4):331-7. doi: 10.1093/jjco/hyt235. Epub 2014 Jan 30.
10
Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.头颈部癌症患者放疗后原发性甲状腺功能减退症:甲状腺剂量-体积限制与长期内分泌结果的外部验证。
Radiother Oncol. 2022 Dec;177:105-110. doi: 10.1016/j.radonc.2022.10.034. Epub 2022 Nov 3.

引用本文的文献

1
Early proteomic response in thyroid gland after 131I administration in female Balb/c mice.雌性Balb/c小鼠给予131I后甲状腺的早期蛋白质组学反应。
Radiat Prot Dosimetry. 2025 Aug 26;201(13-14):887-898. doi: 10.1093/rpd/ncaf057.
2
European Laryngological Society consensus statement on optimal monitoring schedules after treatment for early glottic cancer: a risk-stratification.欧洲喉科学会关于早期声门癌治疗后最佳监测方案的共识声明:风险分层
Eur Arch Otorhinolaryngol. 2025 Sep;282(9):4699-4710. doi: 10.1007/s00405-025-09609-0. Epub 2025 Aug 4.
3
Clinical and Dosimetric Predictors of Early Onset Postradiation Hypothyroidism in Patients with Head and Neck Malignancies: A Logistic Regression Analysis.

本文引用的文献

1
Determining the Occurrence of Hypothyroidism Following Treatment With Radiation Therapy in Head and Neck Carcinoma Patients and the Associated Role of Risk Factors and Dose-Volume Histograms: A Prospective Study.确定头颈部癌患者放射治疗后甲状腺功能减退症的发生率以及风险因素和剂量体积直方图的相关作用:一项前瞻性研究。
Cureus. 2022 Nov 16;14(11):e31590. doi: 10.7759/cureus.31590. eCollection 2022 Nov.
2
Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors.头颈部癌症的流行病学回顾:定义、趋势和危险因素。
Br Dent J. 2022 Nov;233(9):780-786. doi: 10.1038/s41415-022-5166-x. Epub 2022 Nov 11.
3
头颈部恶性肿瘤患者放疗后早期发生甲状腺功能减退的临床和剂量学预测因素:一项逻辑回归分析
Oncol Ther. 2025 Apr 12. doi: 10.1007/s40487-025-00338-2.
4
Hypothyroidism following immunotherapy predicts more postoperative complication in oral squamous cell carcinoma.免疫治疗后发生的甲状腺功能减退预示着口腔鳞状细胞癌术后会出现更多并发症。
BMC Cancer. 2025 Apr 8;25(1):643. doi: 10.1186/s12885-025-14070-7.
5
Predicting radiation-induced hypothyroidism in nasopharyngeal carcinoma patients using a deep learning model.使用深度学习模型预测鼻咽癌患者放射性甲状腺功能减退症
Clin Transl Radiat Oncol. 2025 Mar 13;52:100946. doi: 10.1016/j.ctro.2025.100946. eCollection 2025 May.
6
Preliminary study on the correlation between thyroid magnetic resonance parameters and radiation dose after radiotherapy for nasopharyngeal carcinoma.鼻咽癌放疗后甲状腺磁共振参数与辐射剂量的相关性初步研究
Front Public Health. 2025 Jan 7;12:1526147. doi: 10.3389/fpubh.2024.1526147. eCollection 2024.
7
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.131碘-碘磷腈(CLR 131)联合外照射放疗用于复发性或转移性头颈癌的安全性和毒性:一项1期单中心、开放标签、单臂、剂量递增和剂量扩展研究的结果
EBioMedicine. 2025 Jan;111:105496. doi: 10.1016/j.ebiom.2024.105496. Epub 2024 Dec 12.
8
Protective Effects of Melatonin against Carcinogen-Induced Oxidative Damage in the Thyroid.褪黑素对致癌物诱导的甲状腺氧化损伤的保护作用。
Cancers (Basel). 2024 Apr 25;16(9):1646. doi: 10.3390/cancers16091646.
Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.
头颈部癌症患者放疗后原发性甲状腺功能减退症:甲状腺剂量-体积限制与长期内分泌结果的外部验证。
Radiother Oncol. 2022 Dec;177:105-110. doi: 10.1016/j.radonc.2022.10.034. Epub 2022 Nov 3.
4
Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES).宫颈癌 III 期临床试验中 IG-IMRT 的晚期毒性(PARCER):时间加权不良事件报告(MOSES)的重新分析。
Radiother Oncol. 2022 Dec;177:16-20. doi: 10.1016/j.radonc.2022.10.013. Epub 2022 Oct 18.
5
Early post-treatment F-FDG PET/CT for predicting radiation-induced hypothyroidism in head and neck cancer.早期治疗后 F-FDG PET/CT 预测头颈部癌症放射性甲状腺功能减退症。
Cancer Imaging. 2022 Oct 10;22(1):59. doi: 10.1186/s40644-022-00494-y.
6
Incidence of radiation-induced hypothyroidism following head and neck irradiation: a single-center analysis.头颈部放疗后放射性甲状腺功能减退的发生率:一项单中心分析。
Rep Pract Oncol Radiother. 2022 Jul 29;27(3):479-489. doi: 10.5603/RPOR.a2022.0055. eCollection 2022.
7
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.随机Ⅱ期临床试验:质子颅脊髓放疗对比光子累及野放疗治疗实体瘤性脑膜转移瘤患者。
J Clin Oncol. 2022 Nov 20;40(33):3858-3867. doi: 10.1200/JCO.22.01148. Epub 2022 Jul 8.
8
Predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma survivors after intensity-modulated radiotherapy.调强放疗后鼻咽癌生存者放射性甲状腺功能减退症的预测因素。
Radiat Oncol. 2022 Mar 21;17(1):57. doi: 10.1186/s13014-022-02028-z.
9
Dysphagia, hypothyroidism, and osteoradionecrosis after radiation therapy for head and neck cancer.头颈部癌放疗后的吞咽困难、甲状腺功能减退和放射性骨坏死。
Laryngoscope Investig Otolaryngol. 2021 Dec 10;7(1):108-116. doi: 10.1002/lio2.711. eCollection 2022 Feb.
10
Factors predictive of the development of hypothyroidism after intensity-modulated radiation therapy for pharyngeal cancer.调强放疗治疗咽癌后发生甲状腺功能减退症的预测因素。
Acta Otolaryngol. 2021 Nov;141(11):1022-1026. doi: 10.1080/00016489.2021.1998615. Epub 2021 Nov 5.